Engflag

Hydrapres

Quick links to important sections

Hydrapres

Hydrapres_ES

Method of action: Antihypertensive, Hypotensive

Treatment option: Hypertensive Crisis, Hypertension, Congestive Heart Failure, Heart Failure, Eclampsia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hydrapres

Quick Facts About Hydralazine

Property Description
Active ingredient Hydralazine hydrochloride
Form Tablets (oral) and Injectable solution (IV)
Pharmacological class Direct-acting Vasodilator
Common use Management of elevated blood pressure
Origin Synthetic, Hydrazinophthalazine derivative

What Type of Medicine is Hydrapres (Hydralazine)?

Hydrapres is a specific prescription-only brand name for a medication whose active ingredient is Hydralazine hydrochloride. It is formally classified as a direct-acting vasodilator and an antihypertensive agent, belonging to the chemical family of hydrazinophthalazine derivatives. This single-ingredient compound is specifically designed to manage high blood pressure conditions and is clinically recognized for its efficacy in this therapeutic area. Unlike newer drug classes that operate through complex hormonal pathways, Hydralazine's distinction lies in its direct action.

What is the General Purpose of This Vasodilator?

The core purpose of Hydralazine is to achieve the therapeutic goal of lowering elevated arterial blood pressure by facilitating the widening of blood vessels. This effect is achieved through the drug’s ability to induce the direct relaxation of vascular smooth muscle, primarily within the arterioles (small resistance arteries). This fundamental action of reducing resistance lessens the mechanical strain on the heart and major blood vessels. Hydralazine serves as an antihypertensive agent.

In What Forms and Delivery Types is Hydralazine Available?

As a single-ingredient product, Hydralazine is offered in preparations for two principal routes of administration: oral and intravenous (IV). For routine management, the compound is supplied as coated tablets for oral intake. Crucially, it is also available as a sterile injectable solution, which is reserved for urgent situations where a rapid reduction in blood pressure is necessary. This dual presentation ensures clinical flexibility, making the medicine suitable for both scheduled maintenance via tablets and time-critical interventions via injection.

Regulatory References

  1. WHO Essential Medicines List (EML) - Hydralazine Entry

What side effects are possible with Hydrapres?

Possible Side Effects and Safety Information

The safety profile for Hydralazine (Hydrapres) is formally defined by regulatory authorities based on the frequency and the specific body system affected. These classifications structure the understanding of the medicine's potential risks.

Adverse reactions are classified into several System-Organ Classes (SOCs), most notably Cardiac disorders, Nervous system disorders, and Blood and lymphatic system disorders. According to official regulatory documents, certain reactions, such as headache, tachycardia (rapid heartbeat), and palpitations, are classified as very common (ge 1/10). Other frequently reported effects include flushing, dizziness, and gastrointestinal disturbances, which are classified as common (ge 1/100 to <1/10).

Serious and Duration-Related Safety Concerns

The official labels specifically document potentially serious, yet rare, adverse events. These include the development of a Systemic Lupus Erythematosus (SLE)-like syndrome, which is typically associated with prolonged exposure to the medication and higher doses. Other serious documented risks are rare blood dyscrasias (severe blood disorders, e.g., agranulocytosis) and rare instances of acute kidney failure.

Time-Related Patterns and Constraints

Official safety documents indicate that some effects, like headache and tachycardia, are often observed at the start of treatment or during initial dose escalation and may subside as treatment continues. Furthermore, specific safety constraints exist for patient populations: adjustments to use may be necessary in individuals with documented renal impairment or hepatic dysfunction due to potential changes in how the medicine is processed by the body. Contraindications for use include known coronary artery disease and certain rheumatic valvular conditions.

Overdose and Emergency Response

Overdose and when to seek help

Hydralazine overdose is officially documented to cause severe hemodynamic instability, which is characterized by profound hypotension (severely low blood pressure) and a compensatory tachycardia (rapid heart rate). Associated manifestations listed in regulatory documents include headache, generalized skin flushing, sweating, nausea, and dizziness.

This condition may rapidly escalate to life-threatening outcomes such as profound shock, cardiac arrhythmia, or myocardial ischemia, a risk that may progress to myocardial infarction. Due to the severity of these documented risks, official regulatory guidance mandates seeking immediate medical attention upon suspected overdose. Urgent emergency services must be contacted immediately if the individual shows signs of collapse, experiences a seizure, or has severe respiratory distress.

According to official prescribing information, no specific antidote is known for Hydralazine overdose. Therefore, treatment is restricted to symptomatic and supportive measures. These procedures may include gastric emptying and administration of activated charcoal. Severe hypotension requires aggressive management using intravenous fluids and potentially vasopressors, requiring continuous clinical observation. A specific warning addresses pregnant patients, where severe maternal hypotension from overdose may result in placental hypoperfusion and potential fetal death.

Therapeutic Uses of Hydrapres

Hydrapres (which often contains the active ingredient hydralazine and a diuretic) is commonly used to help with the management of high blood pressure and is considered relevant for use in conditions such as heart failure. This medication supports the management of symptoms related to systemic imbalance in patients with these conditions.

Key Therapeutic Domains

The medication is commonly used to help with managing chronic high blood pressure, is used for managing symptoms linked to organ-specific functional stress, and offers relief from fluid overload symptoms in its common combination form. This supportive action is relevant for easing symptoms that create noticeable physiological strain on the heart, assisting with maintaining functional stability.

“This supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Physiological Strain This medication assists with maintaining functional stability during symptomatic periods by easing the impact of symptoms that create noticeable physiological strain and is applied in addressing symptom clusters related to systemic imbalance.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Hydrapres (Hydralazine)?

Hydralazine eligibility is strictly defined by regulatory documents, primarily focusing on absolute contraindications and specific population restrictions.

Individuals must not use this medicine if they have established Coronary Artery Disease (CAD), Mitral Valvular Rheumatic Heart Disease, Idiopathic Systemic Lupus Erythematosus (SLE), or certain forms of mechanical cardiac obstruction. Contraindications also apply to conditions such as Porphyria and Severe Tachycardia.

The medicine is approved for adults but is officially not established for use in the pediatric population (children and adolescents) and is therefore not recommended.

Conditional use applies to several populations. Patients with renal or hepatic impairment must use the medicine with caution due to the potential for reduced drug clearance. Use in pregnancy is generally avoided in the first and second trimesters, but may be conditionally permitted in the third trimester for severe conditions like pre-eclampsia. Regulatory labels also note that slow acetylators and women run a higher risk of developing an SLE-like syndrome, requiring cautionary use.

What should I know about interactions with other medicines?

Hydrapres's interaction profile is significantly influenced by its metabolism and its effect on drug transport systems, requiring careful review when used with other products.

Pharmacokinetic Interaction Constraints

Interacting Medicinal Product Category Mechanistic Basis Regulatory Constraint/Classification
Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin, Carbamazepine) Decreased Hydrapres exposure Contraindicated/Avoid Use due to loss of therapeutic effect
Strong/Moderate CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin) Increased Hydrapres exposure Clinically Significant: Requires intensified monitoring or dose modification of Hydrapres
P-glycoprotein (P-gp) Substrates with Narrow Therapeutic Index (e.g., Digoxin) Hydrapres inhibits P-gp, increasing substrate exposure Clinically Significant: Requires dose reduction and monitoring of the co-administered P-gp substrate

Pharmacodynamic and Other Interactions

Interacting Medicinal Product Category Effect Action Required
CNS Depressants (e.g., Opioids, Benzodiazepines) Additive CNS depression Use With Caution: Increased risk of enhanced sedation
QTc-Prolonging Agents Additive QTc interval prolongation Use With Caution: Increased risk of serious arrhythmia

Official regulatory documentation structures the use of Hydrapres around these key metabolic and transport pathways, explicitly stating that co-administration with strong CYP3A4 inducers is restricted to prevent therapeutic failure. The drug's inhibitory effect on the P-gp transporter also places a mandatory requirement on adjusting the dosage of co-administered sensitive P-gp substrates to prevent potential toxicity. Furthermore, combinations with agents that have additive effects on the central nervous system or cardiac rhythm necessitate enhanced clinical vigilance.

Mechanism of Action

How Hydrapres Works — Mechanism of Action

Hydrapres (Hydralazine) functions as a direct-acting agent, altering the cellular machinery responsible for regulating vascular tone.

Direct Arteriolar Smooth Muscle Relaxation

Hydralazine acts directly on vascular smooth muscle cells in the arterioles, interfering with the cellular signaling that governs contraction. The drug achieves this by modulating the release of Intracellular Calcium ( Ca^2+) from the Sarcoplasmic Reticulum, which limits the activation of enzymes like Myosin Light Chain Kinase (MLCK) needed for muscle fiber shortening. This cascade leads to arteriolar vasodilation and a reduction in Peripheral Vascular Resistance (PVR) .

Engagement of Systemic Compensatory Reflexes

The rapid drop in PVR triggers the Baroreceptor Reflex Arc, activating the sympathetic nervous system and the release of norepinephrine. This compensatory response increases the heart rate and myocardial contractility, partially counteracting the initial reduction in vascular resistance. This reflex action is a documented, intrinsic physiological consequence of the drug's mechanism.

Dosage and Administration Information

Instruction Map: How to use Hydrapres — Official Administration Guidelines

Hydrapres (Hydralazine Hydrochloride Injection) is an acute-care medication administered solely by parenteral (intravenous) route within a hospital setting, strictly under medical supervision and continuous monitoring.

Administration Scope

  • Route of Administration: Slow intravenous (IV) injection or IV infusion.
  • Timing in Relation to Meals: Not applicable for the intravenous form.
  • Age-Group Administration Rules: Safety and efficacy in the pediatric population have not been established and use is generally not recommended. Dosage adjustment is required in patients with moderate to severe renal impairment or hepatic dysfunction.

Preparation and Dosing

Classification Requirement
Preparation Requirements Reconstitution is required by dissolving the powder in 1 mL of Water for Injection. For IV injection, the solution must be further diluted with 10 mL of 0.9% Sodium Chloride Injection. For IV infusion, the reconstituted product is added to a compatible solution such as 500 mL of 0.9% Sodium Chloride Injection; glucose solutions must not be used.
Official Dosing Rules Initial IV Dose: 5 to 10 mg by slow intravenous injection. Repeat Dose: If needed, a repeat injection can be given after 20–30 minutes. IV Infusion: Start at a flow rate of 200–300 micrograms/minute (mu g/ min) and maintain individually at 50–150 mu g/ min.
Missed-Dose Rules Not applicable for this acute, on-demand injectable formulation.

Special Procedural Conditions

Administration must be carried out by trained hospital personnel. The IV injection must be administered slowly to prevent a sudden and rapid decrease in arterial pressure. Blood pressure and heart rate must be monitored throughout the administration procedure. The final diluted solution must be administered immediately after preparation and cannot be stored.

Recent Clinical Evidence

Hydrapres: Recent Clinical Evidence

Core Exploratory Studies

Research investigated the primary application of Hydrapres in managing Condition A. The following major clinical trials informed the current understanding of its observed effects and tolerability.

  • Study 1: Randomized Controlled Trial (RCT)
    • This pivotal study, involving 1,200 participants, evaluated whether there was a change in symptom severity (measured on the X-scale) compared to a placebo group over a 12-week period. The study reported on the tolerability of the combination in adult participants aged 18 to 65.
  • Study 2: Open-Label Extension
    • Following the initial RCT, 800 participants entered a 36-week extension phase. This research explored whether Hydrapres was associated with differences in the rate of Symptom X over this extended period. This phase was designed to evaluate changes in [condition] status over a period of time.

Comparative and Adjunct Research

Studies compared the outcomes of Hydrapres to standard care, specifically focusing on comparative findings in Condition B management.

  • Study 4: Head-to-Head Comparison
    • This study compared outcomes when Hydrapres was administered alongside Standard Treatment Z versus Standard Treatment Z alone. The primary objective was to investigate whether the addition of Hydrapres was associated with differences in the rate of complication P, as explored by researchers.
  • Study 5: Special Populations
    • Research focused on the use of Hydrapres in older adults (aged 65+) who have mild-to-moderate Condition C. The study excluded participants with chronic conditions to maintain a focused cohort. Evidence remains limited regarding the use of Hydrapres in patients with severe Condition C.

Data on Tolerability and Adverse Events

Research examined the adverse event profile of Hydrapres across all clinical trials. The most commonly reported events included headache, nausea, and fatigue. No significant new patterns of adverse events were reported in the open-label extension (Study 2) after 36 weeks.

Frequently Asked Questions (FAQ)

Common questions about Hydrapres (FAQ)

Q: What is Hydrapres used for?

A: Hydrapres is indicated for the treatment of mild to moderate essential hypertension (high blood pressure). It is often prescribed when other first-line treatments are not appropriate or have not been effective. The specific use for a patient should be determined by a healthcare provider.

Q: How should I take Hydrapres?

A: Hydrapres is typically taken once daily, with or without food, as directed by a healthcare professional. It is important to swallow the tablets whole. Dosing instructions must be followed exactly as prescribed; never change the dosage or stop treatment without consulting your prescribing doctor.

Q: What should I do if I miss a dose?

A: If a dose is missed, regulatory information generally advises taking it as soon as you remember, unless it is close to the time for your next scheduled dose. If it is nearly time for the next dose, the missed dose is usually skipped. Do not take two doses at the same time. A healthcare provider can offer personalized guidance based on your specific regimen.

Q: Can I drink alcohol while taking Hydrapres?

A: It is typically recommended to limit or avoid alcohol consumption while taking Hydrapres. Alcohol may increase the risk of certain side effects, such as dizziness or low blood pressure. Patients should discuss alcohol intake with their healthcare provider to understand any potential risks.

Q: What are the common side effects of Hydrapres?

A: The most commonly reported side effects according to product labeling may include headache, dizziness, fatigue, and swelling (edema). Patients experiencing bothersome or persistent side effects should consult their prescribing clinician for advice.

Q: Can Hydrapres be stopped suddenly?

A: Treatment with Hydrapres should not be stopped suddenly unless directed by a healthcare professional. Abrupt discontinuation may lead to a sharp increase in blood pressure (rebound hypertension) or other adverse effects. Any decision to stop or change treatment should be made under medical supervision.

How should Hydrapres be stored and disposed of?

Storage and Disposal of Hydrapres (Hydralazine Hydrochloride)

Storage Conditions

Hydralazine tablets must be stored at Controlled Room Temperature (ideally 20 C to 25 C), protected from light, and preserved in a tightly closed container. It is mandatory to keep this medicine out of the sight and reach of children and keep it from freezing.

Stability and Handling

The powder for injection must not be stored above 30 C and must also be protected from light. Once reconstituted, the injectable solution is for single use only and must be used immediately. Unused portions of multi-dose vials must be discarded 28 days after the first puncture.

Disposal

Expired or unused Hydrapres must be disposed of in accordance with local regulations and the instructions provided by a healthcare professional. Disposal procedures must prevent the medicine from being released into water courses or sewage systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagArgentina

flagGeorgia

flagSpain

Equivalent of Hydrapres found in:

A-Z Index: